| 1. |
Engel C,Brunkhorst FM,Bone HG,et al.Epidemiology of sepsis in Germany:results from a national prospective multicenter study.Intensive Care Med,2007,33(4):606-618.
|
| 2. |
Solomkin JS,Mazuski JE,Bradley JS,et al.Diagnosis and management of complicated intra-abdominal infection in adults and children:guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.Clin Infect Dis,2010,50(2):133-164.
|
| 3. |
Eckmann C,Dryden M,Montravers P,et al.Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines? a commentary and an alternative European approach according to clinical definitions.Eur J Med Res,2011,16(3):115-126.
|
| 4. |
Weigelt JA.Empiric treatment options in the management of complicated intra-abdominal infections.Cleve Clin J Med,2007,74(Suppl 4):S29-S37.
|
| 5. |
Sartelli M,Viale P,Catena F,et al.2013 WSES guidelines for management of intra-abdominal infections.World J Emerg Surg,2013,8(1):3.
|
| 6. |
Sartelli M,Viale P,Koike K,et al.WSES consensus conference:Guidelines for first-line management of intra-abdominal infections.World J Emerg Surg,2011,6:2.
|
| 7. |
Sartelli M,Catena F,Di Saverio S,et al.Current concept of abdominal sepsis:WSES position paper.World J Emerg Surg,2014,9(1):22.
|
| 8. |
Lehner S,Grabein B,Pfaller P,et al.Relevance of ESBL-producing pathogens for clinical surgery:diagnostics,therapy,and prevention.Chirurg,2009,80(6):527-536.
|
| 9. |
Wilcox MH.The tide of antimicrobial resistance and selection.Int J Antimicrob Agents,2009,34 Suppl 3:S6-S10.
|
| 10. |
Bassetti M,Nicolini L,Repetto E,et al.Tigecycline use in serious nosocomial infections:a drug use evaluation.BMC Infect Dis,2010,10:287.
|
| 11. |
Swoboda S,Ober M,Hainer C,et al.Tigecycline for the treatment of patients with severe sepsis or septic shock:a drug use evaluation in a surgical intensive care unit.J Antimicrob Chemother,2008,61(3):729-733.
|
| 12. |
Babinchak T,Ellis-Grosse E,Dartois N,et al.The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections:analysis of pooled clinical trial data.Clin Infect Dis,2005,41(Suppl 5):S354-S367.
|
| 13. |
Fomin P,Koalov S,Cooper A,et al.The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections-the European experience.J Chemother,2008,20 Suppl 1:12-19.
|
| 14. |
Bodmann KF,Heizmann WR,von Eiff C,et al.Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study:safety profile and efficacy of tigecycline in different treatment modalities.Chemotherapy,2012,58(4):282-294.
|
| 15. |
Montravers P,Lepape A,Dubreuil L,et al.Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections:results of the French prospective,observational EBⅡA study.J Antimicrob Chemother,2009,63(4):785-794.
|
| 16. |
Swenson BR,Metzger R,Hedrick TL,et al.Choosing antibiotics for intra-abdominal infections:what do we mean by "high risk"?.Surg Infect (Larchmt),2009,10(1):29-39.
|
| 17. |
Harbarth S,Uckay I.Are there patients with peritonitis who require empiric therapy for enterococcus?.Eur J Clin Microbiol Infect Dis,2004,23(2):73-77.
|
| 18. |
Birmingham MC,Rayner CR,Meagher AK,et al.Linezolid for the treatment of multidrug-resistant,gram-positive infections:experience from a compassionate-use program.Clin Infect Dis,2003,36(2):159-168.
|
| 19. |
Maseda E,Denis SE,Riquelme A,et al.Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.Rev Esp Quimioter,2013,26(1):56-63.
|
| 20. |
Eckmann C,Dryden M.Treatment of complicated skin and soft-tissue infections caused by resistant bacteria:value of linezolid,tigecycline,daptomycin and vancomycin.Eur J Med Res,2010,15(12):554-563.
|
| 21. |
Montravers P,Dupont H,Gauzit R,et al.Candida as a risk factor for mortality in peritonitis.Crit Care Med,2006,34(3):646-652.
|
| 22. |
Pappas PG,Kauffman CA,Andes D,et al.Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America.Clin Infect Dis,2009,48(5):503-535.
|
| 23. |
Dinubile MJ,Friedland I,Chan CY,et al.Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections:observations from two randomized comparative clinical trials of ertapenem therapy.Eur J Clin Microbiol Infect Dis,2005,24(7):443-449.
|
| 24. |
Giske CG,Monnet DL,Cars O,et al.Clinical and economic impact of common multidrug-resistant gram-negative bacilli.Antimicrob Agents Chemother,2008,52(3):813-821.
|
